Medline Reports Q1 2026 Results and Raises Full Year Organic Sales Guidance

Summary

Medline Inc. reported its first quarter 2026 results, showing net sales of $7.4 billion, a 10.7% increase from the prior year, and net income of $239 million, a 25.8% decrease. The company attributed the decrease in net income to higher costs of goods sold, increased operating expenses, and an employee bonus related to the IPO. Adjusted EBITDA decreased by 10.6% to $776 million. Medline also raised its full year 2026 Organic Sales guidance range to 8.5% to 9.5%, up from the previous range of 8% to 9%. The company remains confident in its ability to support strong customer demand and position for sustained growth.